Atossa Therapeutics, Inc.
NASDAQ: ATOS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven C. Quay
- Employees
- 15
- Headquarters
- Seattle, United States
- IPO year
- 2012
- Market cap
- $15.1M
- Website
- https://www.atossatherapeutics.com
Loading ATOS…
Loading profile data…Frequently asked questions about ATOS
What does Atossa Therapeutics, Inc. (ATOS) do?
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. Thi...
Where does ATOS trade?
Atossa Therapeutics, Inc. (ATOS) trades on the NASDAQ Capital Market.
What sector is ATOS in?
Atossa Therapeutics, Inc. (ATOS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Atossa Therapeutics, Inc.?
Steven C. Quay is the chief executive officer of Atossa Therapeutics, Inc. (ATOS).
Where is Atossa Therapeutics, Inc. headquartered?
Atossa Therapeutics, Inc. is headquartered in United States.
Does ATOS pay a dividend?
Atossa Therapeutics, Inc. (ATOS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ATOS go public?
Atossa Therapeutics, Inc. (ATOS) completed its initial public offering in 2012.